[{"id":"ef460ada-1956-4c98-ae47-6b4d433dca90","acronym":"ReFocus","url":"https://clinicaltrials.gov/study/NCT04526106","created_at":"2021-01-18T21:40:34.651Z","updated_at":"2025-02-25T17:30:23.437Z","phase":"Phase 1/2","brief_title":"REFOCUS: a First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients with ICC and Other Advanced Solid Tumors","source_id_and_acronym":"NCT04526106 - ReFocus","lead_sponsor":"Elevar Therapeutics","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 mutation • FGFR2 fusion","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 mutation • FGFR2 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lirafugratinib (RLY-4008)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 490","initiation":"Initiation: 09/02/2020","start_date":" 09/02/2020","primary_txt":" Primary completion: 09/27/2024","primary_completion_date":" 09/27/2024","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2025-01-30"}]